ECSP982523A - Sal tartrato de un dipeptido sustituido - Google Patents
Sal tartrato de un dipeptido sustituidoInfo
- Publication number
- ECSP982523A ECSP982523A ECSP982523A ECSP982523A EC SP982523 A ECSP982523 A EC SP982523A EC SP982523 A ECSP982523 A EC SP982523A EC SP982523 A ECSP982523 A EC SP982523A
- Authority
- EC
- Ecuador
- Prior art keywords
- compound
- tartaric acid
- useful
- acid salt
- osteoporosis
- Prior art date
Links
- 108010016626 Dipeptides Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 102000018997 Growth Hormone Human genes 0.000 abstract 2
- 108010051696 Growth Hormone Proteins 0.000 abstract 2
- 208000001132 Osteoporosis Diseases 0.000 abstract 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 229940011871 estrogen Drugs 0.000 abstract 2
- 239000000262 estrogen Substances 0.000 abstract 2
- 239000000122 growth hormone Substances 0.000 abstract 2
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 abstract 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 abstract 1
- 125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 abstract 1
- 229940122361 Bisphosphonate Drugs 0.000 abstract 1
- 102000055006 Calcitonin Human genes 0.000 abstract 1
- 108060001064 Calcitonin Proteins 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 239000000384 adrenergic alpha-2 receptor agonist Substances 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- -1 bisphosphonate compound Chemical class 0.000 abstract 1
- 229960004015 calcitonin Drugs 0.000 abstract 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- JKKFKPJIXZFSSB-CBZIJGRNSA-N estrone 3-sulfate Chemical compound OS(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 JKKFKPJIXZFSSB-CBZIJGRNSA-N 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229940063238 premarin Drugs 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 239000000186 progesterone Substances 0.000 abstract 1
- 229960003387 progesterone Drugs 0.000 abstract 1
- 230000000580 secretagogue effect Effects 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- 239000011975 tartaric acid Substances 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Esta invención se refiere a la sal de ácido (L)-tartárico o de la 2-amino-N-{1-2,4-difluoro-benciloximetil)-2-oxo-2- [3-oxo-3a-piridin -2-ilmetil-2-(2,2,2-trifluoro-etil)-2,3,3aA, 6,7-hexahidro-pirazolo [4,3-c] piridin -5-il] etil}-2-metil-propionamida, la cual es un secretagogo de la hormona de crecimiento endógena. En otro aspecto, esta invención proporciona determinados productos intermedios que son útiles para la síntesis del compuesto anterior. La sal del ácido (L)-tartárico del compuesto de está invención es útil para el tratamiento y/o prevención de la osteoporosis, resistencia a la insulina y otros trastornos o enfermedades asociadas con la diferencia de hormona del crecimiento. La sal del ácido (L)-tartárico del compuesto de la presente invención es también útil para el tratamiento de la osteoporosis cuando se usa en combinación con: un compuesto bisfosfonato, estrógenos, Premarin y opcionalmente progesterona, un agonista o antagonista de estrógenos o calcitonina. Además,la presente invención se refiere a procedimientos que comprenden la administración de un agonista alfa-2-adrenérgico y de la sal del ácido (L)-tartárico del compuesto de esta invención.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ECSP982523 ECSP982523A (es) | 1998-06-08 | 1998-06-08 | Sal tartrato de un dipeptido sustituido |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ECSP982523 ECSP982523A (es) | 1998-06-08 | 1998-06-08 | Sal tartrato de un dipeptido sustituido |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP982523A true ECSP982523A (es) | 1999-01-26 |
Family
ID=42043444
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSP982523 ECSP982523A (es) | 1998-06-08 | 1998-06-08 | Sal tartrato de un dipeptido sustituido |
Country Status (1)
| Country | Link |
|---|---|
| EC (1) | ECSP982523A (es) |
-
1998
- 1998-06-08 EC ECSP982523 patent/ECSP982523A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO4810383A1 (es) | Sal tartrato de un dipeptido sustituido | |
| US8076316B2 (en) | Steroid compounds and formulations | |
| JP4486258B2 (ja) | ヒト副甲状腺ホルモンの改変、調製および使用 | |
| Mohan et al. | Comparison of bone formation responses to parathyroid hormone (1-34),(1-31), and (2-34) in mice | |
| US7521528B2 (en) | Conformationally constrained parathyroid hormone (PTH) analogs with lactam bridges | |
| AR004367A1 (es) | Compuestos heterociclicos, mezclas diastereomericas composiciones farmaceuticas, uso de los compuestos en la preparacion de medicamentos. | |
| HU213098B (en) | Process for producing decapeptides antagonistic to hormone for releazing lutheinizing-hormone and pharmaceutical compositions containing them as active components | |
| EP0748817A3 (en) | Parathyroid hormone derivatives and their use | |
| US7795220B2 (en) | Conformationally constrained parathyroid hormones with alpha-helix stabilizers | |
| US7799757B2 (en) | Analogs of parathyroid hormone and PTH-related protein as bone anabolic agents | |
| BR0100946A (pt) | Metabólitos de hexahidropirazolo[4,3-c] piridina | |
| US20070203071A1 (en) | Conformationally Constrained Parthyroid Hormone (Pth) Analogs | |
| JP2002060348A (ja) | 身体機能低下の治療のための成長ホルモン分泌促進物質の使用 | |
| ECSP982523A (es) | Sal tartrato de un dipeptido sustituido | |
| Horiuchi et al. | A multiresponse parathyroid hormone assay: an inhibitor has agonist properties in vivo | |
| KR970004039B1 (ko) | 점막 투여시 흡수 촉진제로서의 시클릭 펩티드 | |
| Klein et al. | Parathyroid hormone-like adenylate cyclase-stimulating activity from a human carcinoma is associated with bone-resorbing activity | |
| Saggese et al. | Combined treatment with growth hormone and gonadotropin-releasing hormone analogues in children with isolated growth hormone deficiency | |
| Roumi et al. | Kinetics and disposition of hexarelin, a peptidic growth hormone secretagogue, in rats | |
| Dresner‐Pollak et al. | Evaluation in vivo of a potent parathyroid hormone antagonist:[Nle8, 18, D‐Trp12, Tyr34] bPTH (7–34) NH2 | |
| Escobar et al. | Persistence of autonomous ovarian activity after discontinuation of therapy for precocious puberty in McCune-Albright syndrome | |
| WO2000021523A1 (en) | Methods for regulating bone formation | |
| CN110234334B (zh) | 肌肉萎缩抑制组合物 | |
| D'Souza | The parathyroid hormone family of ligands and receptors | |
| Désir et al. | Endocrine rhythms |